Clinical trials: Metastatic Malignant Neoplasm in the Brain
Brain Metastases, Brain Metastases, Adult
Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases
Pharmacoscopy refers to an ex vivo real-time drug sensitivity profiling platform that has been shown to be of value in the treatment of leukemia (Snijder et al. 2017) (Kornauth et al.
- Trial name
- EViDENCE-BM (NCT06620380)
- Testing
- Pharmacoscopy 1.0, Control
- Where
- 3 sites in Switzerland
- Volunteers
- 102 people
- Sponsor
- University of Zurich
Breast Cancer (Advanced/Metastatic)
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
This is a Phase II, single-arm, Bayesian adaptive trial. The study employs a two-stage design with an interim analysis after 30 evaluable patients and a maximum enrolment of 60 patients.
- Trial name
- HERBRAIN (NCT07905313)
- Testing
- SRS/fSRT+T-Dxd
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Lung Cancer
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Patients will receive AZD9291 at a dose of 80 mg once daily. Intracranial response will be assessed with brain MRI scan, systemic evaluation will be done by PET-CT (Positron Emission Tomography-Computed Tomography) scan.
- Trial name
- NCT02736513
- Testing
- AZD9291
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Soroka University Medical Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Radiosurgery Before Surgery for the Treatment of Brain Metastases
This early phase I trial identifies the side effects of stereotactic radiosurgery before surgery in treating patients with cancer that has spread to the brain (brain metastases).
- Trial name
- NCT04895592
- Testing
- Dexamethasone, Resection, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Emory University
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Non Small Cell Lung, Brain Metastasases
Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases
The goal of this observational study is to learn about the effects of the timing of radiation therapy and immunotherapy in adults with non-small cell lung cancer (NSCLC) that has spread to the brain.
- Trial name
- (RT-ICI) (NCT07638709)
- Testing
- Brain radiotherapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xiangya Hospital of Central South University
Metastatic Brain Cancer
Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.
To investigate the use of a scalp sparing technique of radiotherapy treatment designed to treat the whole brain. Current treatment methods to treat the whole brain with radiotherapy result in complete alopecia as a side effect.
- Trial name
- SPARE (NCT02213536)
- Testing
- VMAT (Volumetric Modulated Arc Therapy)
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- HCA International Limited
Brain Metastases
Preoperative Stereotactic Radiosurgery for Brain Metastases
STEP is a French multicentre, prospective, non-randomized, phase II study designed to assess 6-months local control after pre-operative stereotactic radiosurgery (SRS) for patients with brain metastases
- Trial name
- STEP (NCT04503772)
- Testing
- Preoperative SRS
- Where
- 8 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Jean Perrin
Whole Brain Radiotherapy
Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer
- Trial name
- NCT06611657
- Testing
- Antirotinib hydrochloride
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreas Cancer, Lung Cancer
Stereotactic Magnetic Resonance Guided Radiation Therapy
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.
- Conditions
- Pancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases
- Trial name
- NCT04115254
- Testing
- MR-guided Linac
- Where
- 2 sites in United States
- Volunteers
- 397 people
- Sponsor
- Dana-Farber Cancer Institute
Neurocognitive
Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI
This is a prospective, randomised, positive-controlled, study to assess the neurocognitive function of upfront Osimertinib compared to whole-brain irradiation (WBI) plus Osimertinib in EGFR-mutant (Ex 19Del and L858R) NSCLC…
- Trial name
- NCT04829019
- Testing
- Osimertinib and whole-brain irradiation, Osimertinib
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sun Yat-sen University
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M…
- Trial name
- NCT06352502
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has…
- Trial name
- NCT06132945
- Testing
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Brain Metastases
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and pyrotinib with fulvestrant in ER/PR positive and HER2-positive breast cancer patients with brain metastasis.
- Trial name
- NCT04334330
- Testing
- Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients…
- Trial name
- NCT05746481
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Liza Villaruz, MD
Surgery, Brain Tumor
Neurosurgical Transitional Care Programme
Readmissions increasingly serve as a metric of hospital performance, inviting quality improvement initiatives in both medicine and surgery.
- Conditions
- Surgery, Brain Tumor, Brain Tumor, Recurrent, Brain Pathology
- Trial name
- TCP (NCT03593330)
- Testing
- Transitional Care Programme
- Where
- United Kingdom
- Volunteers
- 242 people
- Sponsor
- Barts & The London NHS Trust
Metastatic Cancer
Radiosurgery With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00030628
- Testing
- radiation therapy, surgery, WBRT
- Where
- 37 sites in United States
- Volunteers
- 480 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Brain Metastases, Non-small Cell Lung Cancer
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis.
- Trial name
- NCT06020066
- Testing
- EGFR-TK Inhibitor, Stereotactic radiotherapy
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Fudan University
Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
This is a multi-center, single-arm, open-label, Phase 2 clinical study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases.
- Trial name
- NCT04339829
- Testing
- Dacomitinib
- Volunteers
- 50 people
- Sponsor
- Guangdong Association of Clinical Trials
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.